WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Tuesday, May 23, 2006

Hide?	**Set Name**	**Query**	**Hit Count**
	DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ		
☐	L14	(L12 and carcinoembryonic)	16
☐	L13	(L12 and (carcinembryonic antigen))	0
☐	L12	(L8 and (anti CEA))	70
☐	L11	@ad<2002	2168
☐	L10	(L8 and @ad<2002)	0
☐	L9	L8 and @py<20021008	178
☐	L8	(L7 and (cytotoxic agent))	178
☐	L7	(L6 and monoclonal)	334
☐	L6	(L5 and CEA)	387
☐	L5	(L4 and cyclophosphamide)	3308
☐	L4	(L3 and (dacarbazine or DTIC))	3408
☐	L3	(L2 and doxorubicin)	7337
☐	L2	(L1 and vincristine)	8910
☐	L1	((antibody) and composition)	139939

END OF SEARCH HISTORY

```
                 Welcome to DialogClassic Web(tm)
 Dialog level 05.11.05D
Last logoff:  19may06 10:19:54
Logon file001 23may06 17:03:46
          *** ANNOUNCEMENTS ***
                    ***
NEW FILES RELEASED
***Regulatory Affairs Journals (File 183)
***Index Chemicus (File 302)
***Inspec (File 202)

RESUMED UPDATING
***File 141, Reader's Guide Abstracts
                    ***
RELOADS COMPLETED
***File 516, D&B--Dun's Market Identifiers
***File 523, D&B European Dun's Market Identifiers
***File 531, American Business Directory
*** MEDLINE has been reloaded with the 2006 MeSH (Files 154 & 155)
*** The 2005 reload of the CLAIMS files (Files 340, 341, 942)
is now available online.
                               ***
DATABASES REMOVED
***File 196, FINDEX
***File 468, Public Opinion Online (POLL)
 Chemical Structure Searching now available in Prous Science Drug
Data Report (F452), Prous Science Drugs of the Future (F453),
IMS R&D Focus (F445/955), Pharmaprojects (F128/928), Beilstein
Facts (F390), Derwent Chemistry Resource (F355) and Index Chemicus
(File 302).
                    ***
 >>>For the latest news about Dialog products, services, content<<<
 >>>and events, please visit What's New from Dialog at <<<
 >>>http://www.dialog.com/whatsnew/.  You can find news about<<<
 >>>a specific database by entering HELP NEWS <file number>.<<<
 * * *

File   1:ERIC 1966-2006/Apr (c) format only 2006 Dialog

      Set  Items  Description
      ---  -----  -----------
Cost is in DialUnits
?

B 155, 159, 10, 203, 35, 5, 467, 73, 434, 34
       23may06 17:04:30 User290558 Session D43.1
            $0.82    0.233 DialUnits File1
     $0.82  Estimated cost File1
     $0.19  INTERNET
     $1.01  Estimated cost this search
     $1.01  Estimated total session cost   0.233 DialUnits

SYSTEM:OS  - DIALOG OneSearch
  File 155:MEDLINE(R) 1951-2006/May 25
         (c) format only 2006 Dialog
 *File 155: Please see HELP NEWS 154
for information about recent updates added to MEDLINE.
  File 159:Cancerlit 1975-2002/Oct
         (c) format only 2002 Dialog
 *File 159: Cancerlit is no longer updating.
```

```
Please see HELP NEWS159.
  File  10:AGRICOLA 70-2006/Apr
         (c) format only 2006 Dialog
  File 203:AGRIS 1974-2006/Mar
         Dist by NAL, Intl Copr. All rights reserved
  File  35:Dissertation Abs Online 1861-2006/Apr
         (c) 2006 ProQuest Info&Learning
  File   5:Biosis Previews(R) 1969-2006/May W2
         (c) 2006 BIOSIS
  File 467:ExtraMED(tm) 2000/Dec
         (c) 2001 Informania Ltd.
 *File 467: F467 will close on February 1, 2006.                        7.
  File  73:EMBASE 1974-2006/May 23
         (c) 2006 Elsevier Science B.V.
  File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec
         (c) 1998 Inst for Sci Info
  File  34:SciSearch(R) Cited Ref Sci 1990-2006/May W2
         (c) 2006 Inst for Sci Info

      Set  Items  Description
      ---  -----  -----------
?

S (HUMANIZED OR CHIMERIC) AND (ANTI (N) CEA (N) MONOCLONAL)
            11077  HUMANIZED
           103389  CHIMERIC
          1977988  ANTI
            53303  CEA
           844057  MONOCLONAL
             1478  ANTI(N)CEA(N)MONOCLONAL
      S1       87  (HUMANIZED OR CHIMERIC) AND (ANTI (N) CEA (N) MONOCLONAL)
?

S (COMPOSITION AND (CYTOTOXIC (N) AGENT))
          1402679  COMPOSITION
           403025  CYTOTOXIC
          1816893  AGENT
            12624  CYTOTOXIC(N)AGENT
      S2       88  (COMPOSITION AND (CYTOTOXIC (N) AGENT))
?


Set      Items   Description
S1          87   (HUMANIZED OR CHIMERIC) AND (ANTI (N) CEA (N) MONOCLONAL)
S2          88   (COMPOSITION AND (CYTOTOXIC (N) AGENT))
?

S S1 AND S2
               87  S1
               88  S2
      S3        0  S1 AND S2
?


Set      Items   Description
S1          87   (HUMANIZED OR CHIMERIC) AND (ANTI (N) CEA (N) MONOCLONAL)
S2          88   (COMPOSITION AND (CYTOTOXIC (N) AGENT))
S3           0   S1 AND S2
?
```

```
S S1 AND (CYTOTOXIC (N) AGENT)
               87  S1
           403025  CYTOTOXIC
          1816893  AGENT
            12624  CYTOTOXIC(N)AGENT
      S4        4  S1 AND (CYTOTOXIC (N) AGENT)
?

RD S4
      S5        1  RD S4  (unique items)
?

TYPE S5/MEDIUM,K/1

  5/K/1     (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2006 Dialog. All rts. reserv.

15231858   PMID: 15634649
 A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab,
 inhibits  tumor  growth  and  sensitizes  human  medullary  thyroid  cancer
 xenografts to dacarbazine chemotherapy.
  Stein Rhona; Goldenberg David M
  Garden State Cancer Center, Center for Molecular Medicine and Immunology,
Belleville, New Jersey 07109, USA. rstein@gscancer.org
  Molecular   cancer   therapeutics  (United  States)   Dec  2004,  3   (12)
 p1559-64,  ISSN 1535-7163--Print   Journal Code: 101132535
  Publishing Model Print
  Document type: Journal Article
  Languages: ENGLISH
  Main Citation Owner: NLM
  Record type: MEDLINE; Completed

  ... MAb,  labetuzumab,  has  direct,  specific, antitumor effects in this
model, without conjugation to a cytotoxic  agent . In addition, labetuzumab
sensitizes these tumor cells to chemotherapy with an effective drug in this
...
?


Set      Items   Description
S1          87   (HUMANIZED OR CHIMERIC) AND (ANTI (N) CEA (N) MONOCLONAL)
S2          88   (COMPOSITION AND (CYTOTOXIC (N) AGENT))
S3           0   S1 AND S2
S4           4   S1 AND (CYTOTOXIC (N) AGENT)
S5           1   RD S4  (unique items)
?

RD S1
      S6       38  RD S1  (unique items)
?

TYPE S6/MEDIUM,K/1-38

  6/K/1     (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2006 Dialog. All rts. reserv.

15401115   PMID: 15809485
 A  phase  I  trial  combining  high-dose  90Y-labeled  humanized anti-CEA
```

monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer.
Sharkey Robert M; Hajjar George; Yeldell Dion; Brenner Arnold; Burton Jack; Rubin Arnold; Goldenberg David M
Center for Molecular Medicine and Immunology, Garden State Cancer Center, Belleville, New Jersey 07109, USA.
Journal of nuclear medicine - official publication, Society of Nuclear Medicine (United States) Apr 2005, 46 (4) p620-33, ISSN 0161-5505--Print Journal Code: 0217410
Contract/Grant No.: CA79857; CA; NCI; FD-R-001555-01; FD; FDA
Publishing Model Print
Document type: Clinical Trial; Clinical Trial, Phase I; Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

A phase I trial combining high-dose 90Y-labeled humanized anti - CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer.
This trial determined the pharmacokinetics, dosimetry, and dose-limiting toxicity of 90Y-hMN-14 IgG (humanized anticarcinoembryonic antigen [CEA, or CEACAM5] monoclonal antibody; labetuzumab), combined with doxorubicin and peripheral blood stem...

6/K/2 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2006 Dialog. All rts. reserv.

15231858 PMID: 15634649
A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy.
Stein Rhona; Goldenberg David M
Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, New Jersey 07109, USA. rstein@gscancer.org
Molecular cancer therapeutics (United States) Dec 2004, 3 (12) p1559-64, ISSN 1535-7163--Print Journal Code: 101132535
Publishing Model Print
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer...
... and apoptotic pathways. The purpose of this study was to investigate the effect that an anti - CEA monoclonal antibody (MAb) may have on the growth of medullary thyroid cancer (MTC), a CEA-expressing...

...s.c., we compared tumor growth in untreated mice with that of mice given the humanized anti-CEA MAb labetuzumab or an isotype-matched control MAb. The effects of time of...

... MAb dose response, specificity of response, and combination with dacarbazine (DTIC) chemotherapy were studied. The humanized anti-CEA MAb, labetuzumab, has direct, specific, antitumor effects in this model, without conjugation to...

6/K/3 (Item 3 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2006 Dialog. All rts. reserv.

14821573 PMID: 15002034
Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins.
Ma Qiangzhong; DeMarte Luisa; Wang Yawen; Stanners Clifford Paul; Junghans Richard Paul
Division of Hematology-Oncology, Beth Israel Deaconess Medical Center and Harvard Institute of Human Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA.
Cancer gene therapy (England) Apr 2004, 11 (4) p297-306, ISSN 0929-1903--Print Journal Code: 9432230
Publishing Model Print
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

Chimeric immunoglobulin-T-cell receptor (IgTCR)-modified T cells ("designer T cells") kill tumor cells based...
...a monomer size of 85kDa. The A3B3 CEA component of the CEA-Fc bound to anti - CEA monoclonal antibody MN-14, as well as to the single-chain Fv (sFv) derived from this...

... Fc fusion protein can be used to detect the expression of the anti-CEA IgTCR chimeric receptors on the modified T cells, as well as to serve as an antigen to...

6/K/4 (Item 4 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2006 Dialog. All rts. reserv.

12466255 PMID: 10410144
[Immunoscintigraphy and radioimmunotherapy of cancer using monoclonal antibodies]
Oriuchi N
Dept. of Nuclear Medicine, Gunma University School of Medicine.
Gan to kagaku ryoho. Cancer & chemotherapy (JAPAN) May 1999, 26 (6) p762-7, ISSN 0385-0684--Print Journal Code: 7810034
Publishing Model Print
Document type: Journal Article; Review ; English Abstract
Languages: JAPANESE
Main Citation Owner: NLM
Record type: MEDLINE; Completed

... for immunotherapy. The results of a clinical trial performed at our institution using 99mTc-labeled anti - CEA monoclonal antibody are briefly reviewed. Immunoscintigraphy has shown particular promise as a means of whole body...

... of solid tumors is still a major difficulty. Elimination of the immune response by generating humanized monoclonal antibodies, which are virtually devoid of immunogenicity, is necessary to allow repeated administration. This...

6/K/5 (Item 5 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2006 Dialog. All rts. reserv.

12076840 PMID: 10541369
Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study.
Behr T M; Salib A L; Liersch T; Behe M; Angerstein C; Blumenthal R D; Fayyazi A; Sharkey R M; Ringe B; Becker H; Wormann B; Hiddemann W; Goldenberg D M; Becker W
Department of Nuclear Medicine, Georg-August-University of Gottingen, Germany. tmbehr@med.uni-goettingen.de
Clinical cancer research - an official journal of the American Association for Cancer Research (UNITED STATES) Oct 1999, 5 (10 Suppl) p3232s-3242s, ISSN 1078-0432--Print Journal Code: 9502500
Contract/Grant No.: CA 54425; CA; NCI; CA39841; CA; NCI
Publishing Model Print
Document type: Clinical Trial; Clinical Trial, Phase I; Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

... day 10 or 20 after tumor inoculation with the 131I-labeled, low affinity anticarcinoembryonic antigen (anti - CEA) monoclonal antibody (MAb), F023C5 (Ka = 10(7) liters/mol), or the high-affinity anti-CEA MAb...

... were entered into a mCi/m2-based Phase I dose escalation study with 131I-labeled humanized version of MN-14, hMN-14. The patients were given single injections, starting at 50...

6/K/6 (Item 6 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2006 Dialog. All rts. reserv.

12031054 PMID: 9867150
Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
Wong J Y; Chu D Z; Yamauchi D; Odom-Maryon T L; Williams L E; Liu A; Esteban J M; Wu A M; Primus F J; Beatty J D; Shively J E; Raubitschek A A
Division of Radiation Oncology, City of Hope National Medical Center and Beckman Research Institute, Duarte, California 91010, USA.
Journal of nuclear medicine - official publication, Society of Nuclear Medicine (UNITED STATES) Dec 1998, 39 (12) p2097-104, ISSN 0161-5505 --Print Journal Code: 0217410
Contract/Grant No.: 33527; PHS; PO1 43904; PHS; RO1 42329; PHS
Publishing Model Print
Document type: Clinical Trial; Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
Chimeric T84.66 (cT84.66) is a high-affinity (1.16x10(11) M(-1)) IgG1

monoclonal...

... toward increasing blood uptake and decreasing liver uptake was observed with increasing protein dose. CONCLUSION: Chimeric T84.66 demonstrated tumor targeting comparable to other radiolabeled intact anti - CEA monoclonal antibodies. Its immunogenicity after single administration was lower than murine monoclonal antibodies. These properties make...

6/K/7 (Item 7 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2006 Dialog. All rts. reserv.

11836669 PMID: 9661814
Kinetic and affinity constants of epitope specific anti-carcinoembryonic antigen (CEA) monoclonal antibodies for CEA and engineered CEA domain constructs.
Hefta L J; Neumaier M; Shively J E
Division of Immunology, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA.
Immunotechnology - an international journal of immunological engineering (NETHERLANDS) Jun 1998, 4 (1) p49-57, ISSN 1380-2933--Print
Journal Code: 9511979
Publishing Model Print
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

... was no difference in affinity for CEA among a murine (mT84.66), a mouse/human chimeric form (cT84.66) or a disulfide deleted version (delta SScT84.66) of this antibody. There...

... was ten-fold less than for CEA. The affinity constants for CEA with several other anti - CEA monoclonal antibodies, including three antibodies which have almost identical CDR sequences (CEA.281, CEA.11 and ...

6/K/8 (Item 8 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2006 Dialog. All rts. reserv.

11724728 PMID: 9537250
Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy.
Clarke P; Mann J; Simpson J F; Rickard-Dickson K; Primus F J
Division of Immunology, Beckman Research Institute of the City of Hope, Duarte, California 91010, USA.
Cancer research (UNITED STATES) Apr 1 1998, 58 (7) p1469-77, ISSN 0008-5472--Print Journal Code: 2984705R
Contract/Grant No.: CA33572; CA; NCI; CA58327; CA; NCI; CA70320; CA; NCI
Publishing Model Print
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

... the cosmid clone, with approximately 19 integrated copies at one chromosomal location. A mouse-human chimeric anti - CEA monoclonal antibody was used to examine CEA expression by immunohistochemical staining of frozen tissue sections. In...

6/K/9 (Item 9 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2006 Dialog. All rts. reserv.

11592489 PMID: 9441773

Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies.

Juweid M; Swayne L C; Sharkey R M; Dunn R; Rubin A D; Herskovic T; Goldenberg D M

Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, New Jersey 07109, USA.

Gynecologic oncology (UNITED STATES) Dec 1997, 67 (3) p259-71, ISSN 0090-8258--Print Journal Code: 0365304
Contract/Grant No.: CA39841; CA; NCI
Publishing Model Print
Document type: Clinical Trial; Clinical Trial, Phase I; Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies.

... reports the results of a phase I therapy trial with intravenously administered 131I-MN-14 anti - CEA monoclonal antibody (MAb) in patients with EOC. METHODS: Fourteen patients with advanced refractory EOC were given...

6/K/10 (Item 10 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2006 Dialog. All rts. reserv.

11591085 PMID: 9438927

Estimating residence times and their associated errors in patient absorbed-dose calculation.

Kaplan D D; Williams L E; Clarke K G; Odom-Maryon T L; Liu A; Lopatin G; Raubitschek A A; Wong J Y

Division of Radiology, City of Hope National Medical Center, Duarte, California 91010, USA.

Journal of nuclear medicine technology (UNITED STATES) Dec 1997, 25 (4) p264-8, ISSN 0091-4916--Print Journal Code: 0430303
Contract/Grant No.: 33527; PHS; 43904; PHS
Publishing Model Print
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

... radiation dosage calculations has been determined. METHODS: Using a modeling algorithm and its associated parameters, chimeric anti - CEA monoclonal antibody (cT84.66) patient organ uptake data and residence times of source organ activity were...

6/K/11 (Item 11 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2006 Dialog. All rts. reserv.

11582722 PMID: 9430476
Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.
Wong J Y; Thomas G E; Yamauchi D; Williams L E; Odom-Maryon T L; Liu A; Esteban J M; Neumaier M; Dresse S; Wu A M; Primus F J; Shively J E; Raubitschek A A
Division of Radiation Oncology, City of Hope National Medical Center and Beckman Research Institute, Duarte, California 91010, USA.
Journal of nuclear medicine - official publication, Society of Nuclear Medicine (UNITED STATES) Dec 1997, 38 (12) p1951-9, ISSN 0161-5505--Print Journal Code: 0217410
Contract/Grant No.: PO1 43904; PHS; RO1 42329; PHS; T32 CA 09477; CA; NCI ; +
Publishing Model Print
Document type: Clinical Trial; Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

Clinical evaluation of indium-111-labeled chimeric anti - CEA monoclonal antibody.
Chimeric T84.66 (cT84.66) is a high-affinity (1.16 x 10[11] M[-1...

... resulting in estimated radiation doses ranging from 2.0 to 617 cGy/mCi 90Y. CONCLUSION: Chimeric T84.66 demonstrated tumor targeting that was comparable to that of other radiolabeled intact anti...

6/K/12 (Item 12 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2006 Dialog. All rts. reserv.

10404360 PMID: 7884504
Radiolabeled chimeric anti-CEA monoclonal antibody compared with the original mouse monoclonal antibody for surgically treated colorectal carcinoma.
Buchegger F; Mach J P; Pelegrin A; Gillet M; Vogel C A; Buclin T; Ryser J E; Delaloye B; Delaloye A B
Department of Surgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Journal of nuclear medicine - official publication, Society of Nuclear Medicine (UNITED STATES) Mar 1995, 36 (3) p420-9, ISSN 0161-5505--Print Journal Code: 0217410
Publishing Model Print
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

Radiolabeled chimeric anti - CEA monoclonal antibody compared with the original mouse monoclonal antibody for surgically treated colorectal carcinoma.
Biodistribution and tumor uptake of a chimeric human-mouse monoclonal antibody (MAb) and the original mouse MAb have been comparatively studied. METHODS: Eighteen patients with suspected colorectal cancer scheduled for surgery underwent immunoscintigraphy with 123I-labeled chimeric anti-CEA

MAb. Iodine-125 and 131I trace-labeled chimeric and original mouse MAb were simultaneously injected for biodistribution studies. RESULTS: Similar serum kinetics and...

... or metastatic colorectal cancer. CONCLUSION: In this dual-label technique, the radioiodinated anti-CEA IgG4 chimeric MAb and the original mouse IgG1 MAb were shown to have very similar behavior in...

6/K/13 (Item 13 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2006 Dialog. All rts. reserv.

10259339 PMID: 8001025
Differences in biodistribution of the anti-(carcinoembryonic antigen) murine monoclonal antibody CE-25, its F(ab')2 fragment and its intact mainly human chimeric form CE 4-8-13. Dependence on tumour size and amount of antibody injected.
Westera G; Rulicke T; Smith A; Duewell S
Department of Radiology, University Hospital, Zurich, Switzerland.
Cancer immunology, immunotherapy - CII (GERMANY) Dec 1994, 39 (6) p375-82, ISSN 0340-7004--Print Journal Code: 8605732
Publishing Model Print
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

...murine monoclonal antibody CE-25, its F(ab')2 fragment and its intact mainly human chimeric form CE 4-8-13. Dependence on tumour size and amount of antibody injected.
... biodistribution of a family of radioiodinated antibodies was studied. The intact mouse anti-(carcinoembryonic antigen) (anti - CEA) monoclonal antibody CE-25, its F(ab')2 fragment and the intact human-mouse chimeric from CE 4-8-13 were evaluated in a model system using the human CEA...

...after 4 days the mAb values increased with increasing antibody dose. The relative retention of chimeric mAb increased with increasing antibody dose 1 day after injection and also slightly after 4...

... retention of mouse mAb in small tumours increased from day 1 to day 4; for chimeric mAb this value decreased. In normal tissues the relative retention of mouse mAb decreased from day 1 to day 4, but the relative retention of chimeric mAb in normal tissue dropped rapidly and changed little afterwards. Thus the biokinetics of antibodies is "species"-dependent: foreign, mainly human, chimeric antibody clears faster from normal mouse tissue than mouse antibody and reaches lower concentrations.

6/K/14 (Item 14 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2006 Dialog. All rts. reserv.

09704032 PMID: 7687926
Specificity of anti-carcinoembryonic antigen monoclonal antibodies and their effects on CEA-mediated adhesion.
Zhou H; Stanners C P; Fuks A
McGill Cancer Center, Montreal, Quebec, Canada.
Cancer research (UNITED STATES) Aug 15 1993, 53 (16) p3817-22,

ISSN 0008-5472--Print Journal Code: 2984705R
Publishing Model Print
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

The carcinoembryonic antigen (CEA) domain specificities of a library of monoclonal anti - CEA antibodies were determined to investigate the mechanisms of homophilic binding involved in CEA-mediated intercellular...

... on stable Chinese hamster ovary transfectants expressing truncated CEA and CEA/nerve cell adhesion molecule chimeric proteins. Epitopes for these antibodies were thus localized on the CEA molecule as follows: monoclonal...

6/K/15 (Item 15 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2006 Dialog. All rts. reserv.

09455712 PMID: 1464034
[Radiolabeled monoclonal antibodies as anti-tumor missiles, their diagnostic success and therapeutic potential]
Les anticorps monoclonaux radiomarques en tant que missiles anti-tumeurs, leurs succes diagnostiques, leur potentiel therapeutique.
Mach J P; Pelegrin A; Folli S; Buchegger F
Institut de Biochimie, Universite de Lausanne, Epalinges.
Bulletin de l'Academie nationale de medecine (FRANCE) Jun 1992, 176 (6) p879-89, ISSN 0001-4079--Print Journal Code: 7503383
Publishing Model Print
Document type: Journal Article ; English Abstract
Languages: FRENCH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

... the clinical level, in a dosimetry study performed at the Institut Gustave Roussy, the same anti - CEA monoclonal antibodies and fragments, labeled with subtherapeutic doses of 131I, were injected in patients with liver...

... of research for improvement of radioimmunotherapy include the design of genetically engineered new forms of humanized antibodies, the synthesis of original chelates for coupling new radioisotopes to antibodies and the development...

6/K/16 (Item 16 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2006 Dialog. All rts. reserv.

09414563 PMID: 1431347
Application of genetically-engineered anti-CEA antibodies for potential immunotherapy of colorectal cancer.
Hardman N; Murray B; Zwickl M; Kolbinger F; Pluschke G
Department of Molecular Biology, CIBA-GEIGY Ltd., Basle-Switzerland.
International journal of biological markers (ITALY) Jul-Sep 1992, 7 (3) p203-9, ISSN 0393-6155--Print Journal Code: 8712411
Publishing Model Print
Document type: Journal Article; Review

Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

Hitherto anti - CEA monoclonal antibodies (MAbs), normally of mouse origin, have been used primarily for clinical diagnosis of colorectal...

... strategies for "humanization" of mouse anti-CEA MAbs by genetic manipulation of immunoglobulin genes. Such humanized , engineered antibodies markedly attenuate the antigenic response directed against the MAb, such that safe, repeated administration to patients has become feasible. Such humanized anti-CEA antibodies can thus be radioactively-labelled and applied for in vivo monitoring and...

6/K/17 (Item 17 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2006 Dialog. All rts. reserv.

08410957 PMID: 2107969
Cloning of the genes for T84.66, an antibody that has a high specificity and affinity for carcinoembryonic antigen, and expression of chimeric human/mouse T84.66 genes in myeloma and Chinese hamster ovary cells.
Neumaier M; Shively L; Chen F S; Gaida F J; Ilgen C; Paxton R J; Shively J E; Riggs A D
Division of Biology, Beckman Research Institute of the City of Hope, Duarte, California 91010.
Cancer research (UNITED STATES) Apr 1 1990, 50 (7) p2128-34, ISSN 0008-5472--Print Journal Code: 2984705R
Contract/Grant No.: CA 43904; CA; NCI
Publishing Model Print
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

... an antibody that has a high specificity and affinity for carcinoembryonic antigen, and expression of chimeric human/mouse T84.66 genes in myeloma and Chinese hamster ovary cells.
... extensively used in the in vitro immunodiagnosis of human colon adenocarcinomas. Among a number of anti - CEA monoclonal antibodies, the murine monoclonal antibody T84.66 shows the highest specificity and affinity for CEA...

... regions for the heavy and light chains. We also report the construction of mouse/human chimeric IgG1 antibody genes using T84.66 variable region genes and human constant region genes. The resulting chimeric gene constructs were transfected into murine myeloma cells (Sp2/0) by electroporation and into Chinese hamster ovary cells by lipofection. The chimeric antibodies obtained exhibited the same specificity and affinity for CEA as that of the T84...

...Sp2/0 transfectants is sufficiently high (900 micrograms/ml) for initial in vivo studies with humanized T84.66.

6/K/18 (Item 1 from file: 159)
DIALOG(R)File 159:Cancerlit
(c) format only 2002 Dialog. All rts. reserv.

02601246 PMID: 99701565

Preclinical and Clinical Findings Support Concurrent Radioimmunotherapy (RAIT) and Chemotherapy (CH) in Patients with Metastatic Medullary Thyroid Cancer (MTC). (Meeting abstract).

Juweid; Stein; Hajjar; Rubin; Machado; Sharkey; Goldenberg
St. Joseph's Hospital & Medical Center, Paterson, NJ.
Proc Annu Meet Am Soc Clin Oncol 1999, 18,
Document Type: MEETING ABSTRACTS
Languages: ENGLISH
Main Citation Owner: NOTNLM
Record type: Completed

Radiolabeled anti - CEA monoclonal antibodies (MAbs) have shown excellent targeting and initial anti-tumor responses in patients with MTC ...

... a clinical phase-I dose-escalation study was initiated to determine safety and MTD of humanized [Superscript 90]Y-MN-14 (hMN-14) combined with dox and peripheral blood stem cell...

6/K/19 (Item 2 from file: 159)
DIALOG(R)File 159:Cancerlit
(c) format only 2002 Dialog. All rts. reserv.

02600701 PMID: 99701020

Radioimmunotherapy of Small Volume Disease of Colorectal Cancer: Results of a Phase-I/II Trial (Meeting abstract).

Behr; Liersch; Canelo; Lorf; Wormann; Hiddemann; Becker; Ringe; Sharkey; Goldenberg; Becker
Departments of Nuclear Medicine, Surgery, and Hematology-Oncology of the Georg-August-University of Gottingen, Gottingen, Germany; and Garden State Cancer Center, Belleville, NJ.
Proc Annu Meet Am Soc Clin Oncol 1999, 18,
Document Type: MEETING ABSTRACTS
Languages: ENGLISH
Main Citation Owner: NOTNLM
Record type: Completed

...K[Subscript a] = 10[Superscript -7] l/mol), twelve subsequent patients were treated with the humanized high-affinity anti-CEA MAb, hMN-14 (K[Subscript a] = 10[Superscript -9] l/mol...

... show that myelotoxicity is the only dose-limiting toxicity of the [Superscript 131]I-labeled monoclonal anti - CEA antibodies. Although many patients have been treated below the MTD, the observed anti-tumor effects...

6/K/20 (Item 3 from file: 159)
DIALOG(R)File 159:Cancerlit
(c) format only 2002 Dialog. All rts. reserv.

02228719 PMID: 96602098

Expression of human carcinoembryonic antigen in transgenic mice (Meeting abstract).

Clarke; Mann; Simpson; Jin; Primus
Beckman Research Inst., City of Hope National Medical Center, Duarte, CA 91010
Proc Annu Meet Am Assoc Cancer Res 1995, 36, ISSN 0197-016X

```
  Document Type: MEETING ABSTRACTS
  Languages: ENGLISH
  Main Citation Owner: NOTNLM
  Record type: Completed
```

... hybridizable fragments were identified in the line negative for fecal CEA. A mouse/human IgG1 chimeric anti - CEA monoclonal antibody was used to examine CEA expression by immunohistochemical staining of frozen tissue sections from...

6/K/21 (Item 1 from file: 35)
DIALOG(R)File 35:Dissertation Abs Online
(c) 2006 ProQuest Info&Learning. All rts. reserv.

01377462 ORDER NO: AADNN-87951

MOLECULAR MECHANISMS OF INTERCELLULAR ADHESION MEDIATED BY CARCINOEMBRYONIC ANTIGEN FAMILY MEMBERS

```
  Author:   ZHOU, HUA
  Degree:   PH.D.
  Year:     1993
  Corporate Source/Institution:  MCGILL UNIVERSITY (CANADA) (0781)
  Source:   VOLUME 55/06-B OF DISSERTATION ABSTRACTS INTERNATIONAL.
            PAGE 2207.  186 PAGES
  ISBN:          0-315-87951-3
```

...used to investigate the mechanism of CEA-CEA binding using CEA truncated and CEA/NCAM chimeric constructs. A novel model has been proposed in which double reciprocal interactions between the V...

...strong binding between CEA on apposing cell surfaces. Furthermore, the specificity of a library of anti - CEA monoclonal antibodies was defined; their effects on CEA-mediated adhesion further support the CEA-binding model.

6/K/22 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 BIOSIS. All rts. reserv.

0015859364 BIOSIS NO.: 200600204759

Monoclonal antibody to CEA, conjugates comprising said antibody and their therapeutic use

AUTHOR: Copley Clive Graham; Edge Michael Derek; Emery Stephen Charles
AUTHOR ADDRESS: Macclesfield, United Kingdom**United Kingdom
JOURNAL: Official Gazette of the United States Patent and Trademark Office Patents JUN 7 2005 2005
PATENT NUMBER: US 06903203 PATENT DATE GRANTED: June 07, 2005 20050607
PATENT CLASSIFICATION: 536-2353 PATENT ASSIGNEE: AstraZeneca UK Ltd.
PATENT COUNTRY: USA
ISSN: 0098-1133
DOCUMENT TYPE: Patent
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: An anti - CEA monoclonal antibody, designated 806.077, of murine origin is useful for the diagnosis and therapy of...

...LIYAGYLAMD Y; and light chain CDR1 SASSSVTYMH, CDR2 STSNLAS, CDR3 QQRSTYPLT. The antibody optionally is humanized and can be in the form

of a conjugate with either an enzyme, such as...
DESCRIPTORS:
CHEMICALS & BIOCHEMICALS: anti - CEA monoclonal antibody...

6/K/23 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 BIOSIS. All rts. reserv.

0015587281 BIOSIS NO.: 200510281781
A phase I trial combining high-dose Y-90-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer
AUTHOR: Sharkey Robert M; Hajjar George; Yeldell Dion; Brenner Arnold; Burton Jack; Rubin Arnold; Goldenberg David M (Reprint)
AUTHOR ADDRESS: Garden State Canc Ctr, Ctr Mol Med and Immunol, 520 Belleville Ave, Belleville, NJ 07109 USA**USA
AUTHOR E-MAIL ADDRESS: dmg.gscancer@att.net
JOURNAL: Journal of Nuclear Medicine 46 (4): p620-633 APR 2005 2005
ISSN: 0161-5505
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

A phase I trial combining high-dose Y-90-labeled humanized anti - CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer

...ABSTRACT: trial determined the pharmacokinetics, dosimetry, and dose-limiting toxicity of Y-90-hMN-14 IgG (humanized anticarcinoembryonic antigen [CEA, or CEACAM5] monoclonal antibody; labetuzumab), combined with doxorubicin and peripheral blood stem...

6/K/24 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 BIOSIS. All rts. reserv.

0015185053 BIOSIS NO.: 200500102118
Clinical-scale radiolabeling of a humanized anticarcinoembryonic antigen monoclonal antibody, hMN-14, with residualizing 131I for use in radioimmunotherapy
AUTHOR: Govindan Serengularn V (Reprint); Griffiths Gary L; Stein Rhona; Andrews Philip; Sharkey Robert M; Hansen Hans J; Horak Ivan D; Goldenberg David M
AUTHOR ADDRESS: Immunomed Inc, 300 Amer Rd, Morris Plains, NJ, 07950, USA** USA
AUTHOR E-MAIL ADDRESS: sgovindan@immunomedics.com
JOURNAL: Journal of Nuclear Medicine 46 (1): p153-159 January 2005 2005
MEDIUM: print
ISSN: 0161-5505 _(ISSN print)
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

Clinical-scale radiolabeling of a humanized anticarcinoembryonic antigen monoclonal antibody, hMN-14, with residualizing 131I for use in radioimmunotherapy
...ABSTRACT: remote, 1-pot" method of radiolabeling and purification for the scaled-up radioiodination of a humanized anti-carcinoembryonic

```
  antigen (CEA) mAb,  humanized  MN-14 (hMN-14; labetuzumab), with an
  optimized residualizing 131I moiety, 131I-IMP-R4. IMP...
DESCRIPTORS:
  CHEMICALS & BIOCHEMICALS:   ...anti-carcinoembryonic antigen monoclonal
    antibody {MN-14} { anti - CEA   monoclonal  antibody} {labetuzumab...
```

6/K/25 (Item 4 from file: 5)

```
DIALOG(R)File   5:Biosis Previews(R)
(c) 2006 BIOSIS. All rts. reserv.

0014714779   BIOSIS NO.: 200400095536
```

CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies

```
AUTHOR: Hansen Hans J (Reprint); Armour Kathryn L
AUTHOR ADDRESS: Scotland, UK**UK
JOURNAL: Official Gazette of the United States Patent and Trademark Office
Patents  1278 (2): Jan. 13, 2004 2004
MEDIUM: e-file
PATENT NUMBER: US 6676924  PATENT DATE GRANTED: January 13, 2004 20040113
PATENT CLASSIFICATION: 424-149  PATENT ASSIGNEE: Immunomedics, Inc.
PATENT COUNTRY: USA
ISSN: 0098-1133 _(ISSN print)
DOCUMENT TYPE: Patent
RECORD TYPE: Abstract
LANGUAGE: English
```

CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies

```
ABSTRACT: A  humanized  monoclonal antibody, comprising the
  complementarity-determining regions of a parental murine Class III,  anti
  - CEA   monoclonal  antibody engrafted to the framework regions of a
  heterologous antibody, wherein the  humanized  monoclonal antibody
  retains the binding specificity of, but is less immunogenic in a
  heterologous host than, the parental murine monoclonal antibody A.
  preferred murine Class III,  anti - CEA   monoclonal  antibody is the
  MN-14 antibody and the preferred heterologous antibody is from a human.
  Also provided are DNA constructs and vectors for producing the  humanized
   monoclonal antibodies, and diagnostic and therapeutic conjugates using
  same.
DESCRIPTORS:
  CHEMICALS & BIOCHEMICALS:   CDR-grafted type III anti-CEA  humanized
    mouse monoclonal antibodies...
  METHODS & EQUIPMENT:  humanized  monoclonal antibody production...
```

6/K/26 (Item 5 from file: 5)

```
DIALOG(R)File   5:Biosis Previews(R)
(c) 2006 BIOSIS. All rts. reserv.

0013853610   BIOSIS NO.: 200200447121
```

High affinity humanized anti-CEA monoclonal antibodies

```
AUTHOR: Anderson W H Kerr; Tempest Philip R (Reprint); Carr Frank J; Harris
  William J; Armour Kathryn
AUTHOR ADDRESS: West Wratting, UK**UK
JOURNAL: Official Gazette of the United States Patent and Trademark Office
Patents  1260 (2): July 9, 2002 2002
MEDIUM: e-file
PATENT NUMBER: US 6417337  PATENT DATE GRANTED: July 09, 2002 20020709
PATENT CLASSIFICATION: 530-38885  PATENT ASSIGNEE: The Dow Chemical Company
PATENT COUNTRY: USA
```

ISSN: 0098-1133
DOCUMENT TYPE: Patent
RECORD TYPE: Abstract
LANGUAGE: English

High affinity humanized anti - CEA monoclonal antibodies

ABSTRACT: Novel humanized monoclonal antibodies, fragments or derivatives thereof which specifically bind carcinoembryonic antigen (CEA) are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express CEA as well as for...
DESCRIPTORS:
CHEMICALS & BIOCHEMICALS: high affinity humanized anti - CEA monoclonal antibodies...

6/K/27 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 BIOSIS. All rts. reserv.

0013300471 BIOSIS NO.: 200100472310
Anti-CEA antibody designated 806.077, hybridoma and method of manufacture
AUTHOR: Copley Clive Graham (Reprint); Edge Michael Derek; Emery Stephen Charles
AUTHOR ADDRESS: Macclesfield, UK**UK
JOURNAL: Official Gazette of the United States Patent and Trademark Office Patents 1249 (3): Aug. 21, 2001 2001
MEDIUM: e-file
PATENT NUMBER: US 6277599 PATENT DATE GRANTED: August 21, 2001 20010821
PATENT CLASSIFICATION: 435-696 PATENT ASSIGNEE: Zeneca Limited, London, UK
PATENT COUNTRY: USA
ISSN: 0098-1133
DOCUMENT TYPE: Patent
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: An anti - CEA monoclonal antibody, designated 806.077, of murine origin is useful for the diagnosis and therapy of...

...LIYAGYLAMD Y; and light chain CDR1 SASSSVTYMH, CDR2 STSNLAS, CDR3 QQRSTYPLT. The antibody optionally is humanized and can be in the form of a conjugate with either an enzyme, such as...

6/K/28 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 BIOSIS. All rts. reserv.

0009706087 BIOSIS NO.: 199598173920
Breast tumor xenograft targeting and therapy studies using radiolabeled chimeric anti-CEA monoclonal antibody T84.66
AUTHOR: Esteban Jose M (Reprint); Raubitschek Andrew; Felder Barbara; Williams Lawrence E; Wong Jeffrey Y C; Shively John E
AUTHOR ADDRESS: Dep. Pathol., Georgetown Univ. Med. Cent., 3900 Reservoir Rd. NW, Washington, DC 20007, USA**USA
JOURNAL: Oncology Reports 2 (2): p237-242 1995 1995
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

Breast tumor xenograft targeting and therapy studies using radiolabeled chimeric anti - CEA monoclonal antibody T84.66

...ABSTRACT: antibody (MAb) that does not cross-react with other CEA-related proteins. It has been humanized and used extensively after radiolabeling in clinical/experimental protocols for localization/therapy of colorectal cancer...

6/K/29 (Item 8 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 BIOSIS. All rts. reserv.

0008071173 BIOSIS NO.: 199243039764
HUMAN ANTI-MOUSE RESPONSE AFTER IMMUNOSCINTIGRAPHY IS WITH CHIMERIC CH ANTI-CEA MONOCLONAL ANTIBODIES MAB
AUTHOR: DELALOYE A B (Reprint); BUCHEGGER F; MACH J P; PELEGRIN A; FOLLI S; HARDMAN N; HEUSSER C; DELALOYE B
AUTHOR ADDRESS: LAUSANNE UNIV, CIBA-GEIGY LTD, BASEL, SWITZERLAND** SWITZERLAND
JOURNAL: Journal of Nuclear Medicine 33 (5 SUPPL): p903-904 1992
CONFERENCE/MEETING: 39TH ANNUAL MEETING OF THE SOCIETY OF NUCLEAR MEDICINE, LOS ANGELES, CALIFORNIA, USA, JUNE 9-12, 1992. J NUCL MED.
ISSN: 0161-5505
DOCUMENT TYPE: Meeting
RECORD TYPE: Citation
LANGUAGE: ENGLISH

HUMAN ANTI-MOUSE RESPONSE AFTER IMMUNOSCINTIGRAPHY IS WITH CHIMERIC CH ANTI - CEA MONOCLONAL ANTIBODIES MAB

6/K/30 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2006 Elsevier Science B.V. All rts. reserv.

13503154 EMBASE No: 2005545185
A phase I trial combining high-dose SUP90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer
Sharkey R.M.; Hajjar G.; Yeldell D.; Brenner A.; Burton J.; Rubin A.; Goldenberg D.M.
Dr. D.M. Goldenberg, Garden State Cancer Center, 520 Belleville Ave., Belleville, NJ 07109 United States
AUTHOR EMAIL: dmg.gscancer@att.net
Journal of Nuclear Medicine (J. NUCL. MED.) (United States) 2005, 46/4 (620-633)
CODEN: JNMEA ISSN: 0161-5505
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 48

A phase I trial combining high-dose SUP90Y-labeled humanized anti - CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer

This trial determined the pharmacokinetics, dosimetry, and dose-limiting toxicity of SUP90Y-hMN-14 IgG (humanized anticarcinoembryonic antigen [CEA, or CEACAM5] monoclonal antibody; labetuzumab), combined with doxorubicin and peripheral blood stem...

6/K/31 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2006 Elsevier Science B.V. All rts. reserv.

05962481 EMBASE No: 1994374656
Differences in biodistribution of the anti(carcinoembryonic antigen) murine monoclonal antibody CE-25, its F(ab')inf 2 fragment and its intact mainly human chimeric form CE 4-8-13. Dependence on tumour size and amount of antibody injected
Westera G.; Rulicke T.; Smith A.; Duewell S.
Department of Radiology, Division of Nuclear Medicine, University Hospital,CH-8091 Zurich Switzerland
Cancer Immunology Immunotherapy (CANCER IMMUNOL. IMMUNOTHER.) (Germany)
1994, 39/6 (375-382)
CODEN: CIIMD ISSN: 0340-7004
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

...monoclonal antibody CE-25, its F(ab')inf 2 fragment and its intact mainly human chimeric form CE 4-8-13. Dependence on tumour size and amount of antibody injected

...biodistribution of a family of radioiodinated antibodies was studied. The intact mouse anti-(carcinoembryonic antigen) (anti - CEA) monoclonal antibody CE-25, its F(ab')inf 2 fragment and the intact human-mouse chimeric from CE 4-8-13 were evaluated in a model system using the human CEA...

...after 4 days the mAb values increased with increasing antibody dose. The relative retention of chimeric mAb increased with increasing antibody dose 1 day after injection and also slightly after 4...

...retention of mouse mAb in small tumours increased from day 1 to day 4; for chimeric mAb this value decreased. In normal tissues the relative retention of mouse mAb decreased from day 1 to day 4, but the relative retention of chimeric mAb in normal tissue dropped rapidly and changed little afterwards. Thus the biokinetics of antibodies is 'species'-dependent: foreign, mainly human, chimeric antibody clears faster from normal mouse tissue than mouse antibody and reaches lower concentrations.
DRUG DESCRIPTORS:
...*carcinoembryonic antibody--drug concentration--cr; *carcinoembryonic antibody--drug combination--cb; *carcinoembryonic antigen--endogenous compound--ec; * chimeric antibody--pharmacokinetics--pk; * chimeric antibody--drug concentration--cr; * chimeric antibody--drug combination --cb; *immunoglobulin f(ab) fragment--pharmacokinetics--pk; *immunoglobulin f(ab) fragment--drug...

6/K/32 (Item 1 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci
(c) 2006 Inst for Sci Info. All rts. reserv.

12367217 Genuine Article#: 756LU No. References: 0
Title: Naked humanized anti-CEA monoclonal antibody, hMN-14, is therapeutically active and is also chemosensitizing in human colon cancer models.

Author(s): Blumenthal R; Osorio L; Goldenberg DM
Corporate Source: Garden State Canc Ctr,Belleville//NJ/
Journal: CLINICAL CANCER RESEARCH, 2003, V9, N16,2,S (DEC 1), P6195S-6195S
ISSN: 1078-0432 Publication date: 20031201
Publisher: AMER ASSOC CANCER RESEARCH, 615 CHESTNUT ST, 17TH FLOOR,
PHILADELPHIA, PA 19106-4404 USA
Language: English Document Type: MEETING ABSTRACT

Title: Naked humanized anti - CEA monoclonal antibody, hMN-14, is therapeutically active and is also chemosensitizing in human colon cancer models.

6/K/33 (Item 2 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci
(c) 2006 Inst for Sci Info. All rts. reserv.

05878723 Genuine Article#: XD639 No. References: 35
Title: Comparison of copper-67- and iodine-125-labeled anti-CEA monoclonal antibody biodistribution in patients with colorectal tumors
Author(s): Delaloye AB (REPRINT) ; Delaloye B; Buchegger F; Vogel CA; Gillet M; Mach JP; Smith A; Schubiger PA
Corporate Source: CHU VAUDOIS,DEPT NUCL MED/CH-1011 LAUSANNE//SWITZERLAND/ (REPRINT); UNIV LAUSANNE,INST BIOCHEM, DEPT NUCL MED/LAUSANNE//SWITZERLAND/; UNIV LAUSANNE,INST BIOCHEM, DEPT SURG/LAUSANNE//SWITZERLAND/; PAUL SCHERRER INST,DIV RADIOPHARM/VILLIGEN//SWITZERLAND/
Journal: JOURNAL OF NUCLEAR MEDICINE, 1997, V38, N6 (JUN), P847-853
ISSN: 0161-5505 Publication date: 19970600
Publisher: SOC NUCLEAR MEDICINE INC, 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316
Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)

Title: Comparison of copper-67- and iodine-125-labeled anti - CEA monoclonal antibody biodistribution in patients with colorectal tumors
Research Fronts: 95-5035 002 (FUNCTION OF SALMONELLA-TYPHIMURIUM OROTATE PHOSPHORIBOSYLTRANSFERASE; CHIMERIC MONOCLONAL-ANTIBODY L6; RECONSTITUTED NA+,K+-ATPASE)
95-6231 002 (TC-99M-LABELED LL2 MONOCLONAL...

6/K/34 (Item 3 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci
(c) 2006 Inst for Sci Info. All rts. reserv.

05745397 Genuine Article#: WU970 No. References: 17
Title: Radiolabelled monoclonal antibodies in clinical and surgical oncology: A review
Author(s): Biassoni L; DAndrea V (REPRINT) ; Biancari F; Santoni F; Dibra A ; DeAntoni E
Corporate Source: VIA NEMORENSE 15,/I-00199 ROME//ITALY/ (REPRINT); ROYAL HOSP NHS TRUST,ST BARTHOLOMEWS HOSP, DEPT NUCL MED/LONDON//ENGLAND/
Journal: PANMINERVA MEDICA, 1997, V39, N1 (MAR), P46-52
ISSN: 0031-0808 Publication date: 19970300
Publisher: EDIZIONI MINERVA MEDICA, CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY
Language: English Document Type: REVIEW (ABSTRACT AVAILABLE)

Research Fronts: 95-7708 001 (CHIMERIC ANTIBODY; IN-111-LABELED HUMAN TUMOR REACTIVE MONOCLONAL IGM AC6C3-2B12; 2-SITE IMMUNOASSAY FOR

```
    CARCINOEMBRYONIC ANTIGEN (CEA))
  95-7865 001   (TC-99M-LABELED  ANTI - CEA   MONOCLONAL -ANTIBODY;
    IMMUNOSCINTIGRAPHY IN COLORECTAL-CANCER; IMAGING OF ENDOTHELIAL-CELL
    ACTIVATION)


  6/K/35     (Item 4 from file: 34)
DIALOG(R)File  34:SciSearch(R) Cited Ref Sci
(c) 2006 Inst for Sci Info. All rts. reserv.

05448482   Genuine Article#: VZ520   No. References: 210
 Title: COPPER RADIONUCLIDES AND RADIOPHARMACEUTICALS IN NUCLEAR-MEDICINE
Author(s): BLOWER PJ; LEWIS JS; ZWEIT J
Corporate Source: KENT & CANTERBURY HOSP,DEPT NUCL MED/CANTERBURYCT1
    3NG/KENT/ENGLAND/; UNIV KENT/CANTERBURY/KENT/ENGLAND/; ROYAL MARSDEN
    HOSP,INST CANC RES,JOINT DEPT PHYS/SUTTON/SURREY/ENGLAND/
Journal: NUCLEAR MEDICINE AND BIOLOGY, 1996, V23, N8 (NOV), P957-980
ISSN: 0883-2897
Language: ENGLISH   Document Type: REVIEW    (Abstract Available)

Research Fronts: 95-5035 002   (FUNCTION OF SALMONELLA-TYPHIMURIUM OROTATE
    PHOSPHORIBOSYLTRANSFERASE;  CHIMERIC  MONOCLONAL-ANTIBODY L6;
    RECONSTITUTED NA+,K+-ATPASE)
  95-0133 001   (PRIMARY ENDOSCOPIC MANAGEMENT OF UPPER...

...001   (BINUCLEAR COMPLEXES; SULFUR LIGANDS; X-RAY CRYSTAL-STRUCTURE)
  95-7865 001   (TC-99M-LABELED  ANTI - CEA   MONOCLONAL -ANTIBODY;
    IMMUNOSCINTIGRAPHY IN COLORECTAL-CANCER; IMAGING OF ENDOTHELIAL-CELL
    ACTIVATION)


  6/K/36     (Item 5 from file: 34)
DIALOG(R)File  34:SciSearch(R) Cited Ref Sci
(c) 2006 Inst for Sci Info. All rts. reserv.

05176470   Genuine Article#: VF011   No. References: 56
 Title: THE USE OF RADIOLABELED MONOCLONAL-ANTIBODIES IN THE DIAGNOSIS OF
   COLORECTAL CARCINOMAS
Author(s): NABI HA
Corporate Source: SUNY BUFFALO,DEPT NUCL MED,105 PARKER HALL,3435MAIN
    ST/BUFFALO//NY/14214
Journal: CLINICAL IMMUNOTHERAPEUTICS, 1996, V6, N3 (SEP), P200-210
ISSN: 1172-7039
Language: ENGLISH   Document Type: REVIEW    (Abstract Available)

...Abstract: and are currently under investigation. Tc-99m arcitumomab, an
    Fab' fragment of IMMU-4, an  anti - CEA   monoclonal  antibody, has
    recently been approved for imaging in colorectal cancer.
...Research Fronts: GLYCOPROTEIN-72; MONOCLONAL-ANTIBODY I-131 CC49;
    RADIOIMMUNOGUIDED SURGERY FOR COLORECTAL-CANCER)
  94-7466 001   ( CHIMERIC  ANTIBODIES; THERAPY OF CANCER; FAB FRAGMENTS)


  6/K/37     (Item 6 from file: 34)
DIALOG(R)File  34:SciSearch(R) Cited Ref Sci
(c) 2006 Inst for Sci Info. All rts. reserv.

03687836   Genuine Article#: PX506   No. References: 27
 Title: DIFFERENCES IN BIODISTRIBUTION OF THE ANTI-(CARCINOEMBRYONIC
   ANTIGEN) MURINE MONOCLONAL-ANTIBODY-CE-25, ITS F(AB')(2)-FRAGMENT AND
```

ITS INTACT MAINLY HUMAN CHIMERIC FORM CE-4-8-23 - DEPENDENCE ON TUMOR SIZE AND AMOUNT OF ANTIBODY INJECTED
Author(s): WESTERA G; RULICKE T; SMITH A; DUEWELL S
Corporate Source: UNIV ZURICH HOSP,DEPT RADIOL,DIV NUCL MED/CH-8091 ZURICH//SWITZERLAND/; UNIV ZURICH HOSP,CENT BIOL LAB/CH-8091 ZURICH//SWITZERLAND/; PAUL SCHERRER INST,DIV RADIOPHARM/VILLIGEN//SWITZERLAND/
Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY, 1994, V39, N6 (DEC), P375-382
ISSN: 0340-7004
Language: ENGLISH   Document Type: ARTICLE   (Abstract Available)

...Title: **MURINE MONOCLONAL-ANTIBODY-CE-25, ITS F(AB')(2)-FRAGMENT AND ITS INTACT MAINLY HUMAN CHIMERIC FORM CE-4-8-23 - DEPENDENCE ON TUMOR SIZE AND AMOUNT OF ANTIBODY INJECTED**

...Abstract: biodistribution of a family of radioiodinated antibodies was studied. The intact mouse anti-(carcinoembryonic antigen) (anti - CEA) monoclonal antibody CE-25, its F(ab')(2) fragment and the intact human-mouse chimeric from CE 4-8-13 were evaluated in a model system using the human CEA...

...after 4 days the mAb values increased with increasing antibody dose. The relative retention of chimeric mAb increased with increasing antibody dose 1 day after injection and also slightly after 4...

...retention of mouse mAb in small tumours increased from day 1 to day 4; for chimeric mAb this value decreased. In normal tissues the relative retention of mouse mAb decreased from day 1 to day 4, but the relative retention of chimeric mAb in normal tissue dropped rapidly and changed little afterwards. Thus the biokinetics of antibodies is ''species''-dependent: foreign, mainly human, chimeric antibody clears faster from normal mouse tissue than mouse antibody and reaches lower concentrations.

6/K/38 (Item 7 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci
(c) 2006 Inst for Sci Info. All rts. reserv.

02120373 Genuine Article#: KA098 No. References: 0
Title: RADIOLABELED MONOCLONAL-ANTIBODIES THEIR PRACTICAL USE IN TUMOR-DETECTION AND THEIR POTENTIAL FOR THERAPY
Author(s): MACH JP; PELEGRIN A; FOLLI S; BUCHEGGER F
Corporate Source: UNIV LAUSANNE,INST BIOCHIM,CHEMIN BOVERESSES 155/CH-1066 EPALINGES//SWITZERLAND/
Journal: BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 1992, V176, N6 (JUN 2), P879-889
ISSN: 0001-4079
Language: FRENCH   Document Type: ARTICLE   (Abstract Available)   (NO REFS KEYED)

...Abstract: the clinical level, in a dosimetry study performed at the Institut Gustave Roussy, the same anti - CEA monoclonal antibodies and fragments, labeled with subtherapeutic doses of I-131, were injected in patients with...

...of research for improvement of radioimmunotherapy include the design of genetically engineered new forms of humanized antibodies, the synthesis of original chelates for coupling new radioisotopes to antibodies and the development...

?